Related Experiment Videos
Xeroderma pigmentosum variant: response to etretinate.
J Berth-Jones1, R A Graham-Brown
1Department of Dermatology, Leicester Royal Infirmary, U.K.
The British Journal of Dermatology
|April 1, 1990
Summary
This study shows etretinate effectively suppressed tumor development in a patient with xeroderma pigmentosum (a rare genetic disorder). The treatment prevented new tumors for 22 months at a 25 mg daily dose.
Area of Science:
- Dermatology
- Oncology
- Genetics
Background:
- Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder characterized by defective DNA repair, leading to extreme sun sensitivity and a high risk of skin cancer.
- Tumorigenesis in XP patients is a significant clinical challenge, often necessitating frequent monitoring and interventions.
Observation:
- A patient with a variant form of xeroderma pigmentosum (XP-V) was treated with etretinate at a dosage of 25 mg daily.
- The treatment was administered over a period of 22 months.
Findings:
- Complete suppression of tumor development was observed during the 22-month treatment period.
- Etretinate demonstrated significant efficacy in preventing new tumor formation in this XP-V patient.
Implications:
- Etretinate may represent a promising therapeutic strategy for managing tumor development in xeroderma pigmentosum.
- Further research is warranted to explore the long-term efficacy and safety of etretinate in XP patients.
- This case highlights the potential of systemic retinoids in cancer prevention for individuals with DNA repair deficiencies.